Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.69 USD
Change Today -0.20 / -0.84%
Volume 700.3K
DYAX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

dyax corp (DYAX) Snapshot

Open
$23.67
Previous Close
$23.89
Day High
$24.52
Day Low
$23.06
52 Week High
04/8/15 - $30.55
52 Week Low
10/13/14 - $9.19
Market Cap
3.5B
Average Volume 10 Days
961.9K
EPS TTM
$-0.14
Shares Outstanding
146.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DYAX CORP (DYAX)

dyax corp (DYAX) Related Bloomberg News

View More Bloomberg News

dyax corp (DYAX) Related Businessweek News

No Related Businessweek News Found

dyax corp (DYAX) Details

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. The company distributes KALBITOR through a network of wholesale, hospital, and specialty pharmacy arrangements. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b clinical study to treat HAE prophylactically. The company has agreements with CVie Therapeutics to develop and commercialize KALBITOR for the treatment of HAE and other angioedema indications in China, Hong Kong, and Macau; and Novellus Biopharma AG to develop and commercialize KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. It also has agreement with CMIC Co., Ltd. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other angioedema indications in Japan; and collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in various territories worldwide. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts.

124 Employees
Last Reported Date: 02/27/15
Founded in 1989

dyax corp (DYAX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $636.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $391.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $449.2K
Executive Vice President, General Counsel and...
Total Annual Compensation: $359.6K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $239.3K
Compensation as of Fiscal Year 2014.

dyax corp (DYAX) Key Developments

Dyax Corp. Provides Update on DX-2930 Clinical and Commercial Supply Initiatives

Dyax Corp. provided an update regarding its ongoing manufacturing initiatives for DX-2930. Discovered by Dyax, DX-2930 is an investigational fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema (HAE) attacks. Dyax’s manufacturing partner, Rentschler Biotechnologie GmbH (Rentschler), is responsible for providing cGMP (Current Good Manufacturing Practice) drug substance for certain future clinical trials and commercial supply. In preparation for commercial-scale production, Rentschler has commenced characterization and validation of the DX-2930 manufacturing processes. In addition, Rentschler will also support Dyax in the preparation of its submissions to regulatory authorities for marketing approval of the product. If DX-2930 is approved, Rentschler will be responsible for producing commercial supply. Dyax and Rentschler entered into a definitive manufacturing services agreement in 2014. DX-2930 is a novel, fully human monoclonal antibody inhibitor of plasma kallikrein (pKal) which is currently being developed as a subcutaneous injection for the prevention of HAE attacks. Uncontrolled pKal activity leads to excessive generation of bradykinin, a vasodilator thought to be responsible for the localized swelling, inflammation and pain characteristically associated with HAE.

Dyax Corp. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for 2015

Dyax Corp. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. For the quarter, total revenue, net was $26.373 million against $19.585 million a year ago. Loss from operations was $5.905 million against $0.411 million a year ago. Net loss was $8.411 million or $0.06 per basic and diluted share against $3.061 million or $0.02 per basic and diluted share a year ago. For the six months, total revenue, net was $46.791 million against $33.702 million a year ago. Loss from operations was $10.553 million against $3.437 million a year ago. Net loss was $15.682 million or $0.11 per basic and diluted share against $8.772 million or $0.07 per basic and diluted share a year ago. The company has reiterated its revenue guidance for 2015. Revenue guidance includes two components: KALBITOR net sales in the range of $60-70 million. Development and license fees in the range of $7-9 million. These fees exclude all potential royalties which would be earned from licensees' sales of LFRP product. The company has revised its operating costs and expenses (cost of product sales, research and development expenses, and selling, general and administrative costs) which are expected to be in the range of $120-125 million, an increase from its previous guidance of $105-110 million. This increase is due to costs associated with the acceleration of the DX-2930 development program and non-cash stock compensation charges.

Dyax Corp. to Report Q2, 2015 Results on Jul 29, 2015

Dyax Corp. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAX:US $23.69 USD -0.20

DYAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $11.42 USD +0.21
Regeneron Pharmaceuticals Inc $536.70 USD -1.30
Shire PLC 5,025 GBp +10.00
View Industry Companies
 

Industry Analysis

DYAX

Industry Average

Valuation DYAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.2x
Price/Book 10.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 31.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYAX CORP, please visit www.dyax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.